Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized study of WTX101 versus standard treatment in adults with Wilson disease
MOH_2018-07-08_002465Phase 3Not yet recruiting
- Sponsor
- Alexion Pharmaceuticals
- Start
- Apr 2018
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of atn-224 in Wilson disease (WD) (2 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Primary efficacy endpoint. Planned start Apr 2018; status: not yet recruiting.
02
Drugs
atn-224
03
Conditions
Wilson disease (WD)
Beyond the preview
Go deeper on MOH_2018-07-08_002465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-07-08_002465.